Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT05739006 2023-08-02

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Phase 1 Unknown

131 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Phase 1/2 Unknown

314 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms

Clinical Trials

I-STOP

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

MiST

Microbiome Immunotherapy Toxicity and Response Evaluation

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

Luscid

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

DYNAPET

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Pembrolizumab + CVA21 in Advanced NSCLC

PEOPLE

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients